Immuron Limited

About

Immuron Limited is a biopharmaceutical company focused on the discovery, development, and global commercialization of polyclonal antibodies, with operations spanning Australia, the United States, and other international markets. The company's activities are structured into two key segments: Research and Development, and Hyperimmune Products. Currently, Immuron markets two key products. Travelan is an over-the-counter (OTC) medicine that helps reduce the risk of traveler's diarrhea and lessens symptoms of minor gastrointestinal issues, while also serving as a dietary supplement for digestive tract protection. Its second product, Protectyn, is an immune supplement formulated to support healthy digestive function and liver health. In its pipeline, an advanced formulation of Travelan (IMM-124E) is undergoing Phase III clinical trials. This variant is being developed not only to further reduce the risk of traveler's diarrhea but also for its potential anti-viral activity against SARS-CoV-2. Another pipeline candidate, IMM-529, is in clinical development with a focus on treating recurrent Clostridium difficile infections. Immuron maintains strategic collaborations, including a research agreement with the Naval Medical Research Center to develop and clinically assess a therapeutic targeting Campylobacter and ETEC infections. Additionally, it has a collaboration with the Walter Reed Army Institute of Research aimed at creating an oral therapeutic for shigellosis. Established in 1994, Immuron Limited is headquartered in Carlton, Australia.

Stock Price